BI 3810477 / Boehringer Ingelheim - LARVOL DELTA

Late Breaking Abstract - Discovery of an MMP7‑driven CTGF proteolytic switch as a new therapeutic intervention in IPF (ERS 2026) - "Although CTGF has long been implicated, therapeutic modulation has failed, as illustrated by the phase 3 failure of pamrevlumab. BI3810477 neutralized NTF-driven signaling, reduced fibrotic responses, and restored alveolar epithelial cell fate in patient-derived cultures, consistently outperforming earlier CTGF targeting agents. Our work explains past therapeutic failures and establishes BI3810477 as a next-generation strategy targeting a pathogenic CTGF species, providing strong rationale for phase 2 advancement."

Late-breaking abstract • Fibrosis • Idiopathic Pulmonary Fibrosis • CTGF • MMP7